Discovery and Crystallography Study of Novel Resorcinol Dibenzyl Ether-Based PD-1/PD-L1 Inhibitors with Improved Drug-like and Pharmacokinetic Properties for Cancer Treatment

Current studies on PD-1/PD-L1 small-molecule inhibitors mainly focus on modifying the linker region between the biphenyl ring and amino acid side chains, or transforming the biphenyl ring into a benzodioxane structure. Herein, we designed and synthesized a series of compounds by introducing a tail at the terminal phenyl ring as small-molecule PD-1/PD-L1 inhibitors. Among them, compound NPH16 exhibited the most potent PD-L1 inhibitory activity (IC50 = 24.4 nM). The X-ray crystal structure further confirmed the high binding affinity of NPH16 to PD-L1 dimer. In the HepG2/Jurkat T cell coculture model, NPH16 promoted HepG2 cell apoptosis dose-dependently. In addition, NPH16 showed excellent in vivo antitumor efficacy (TGI = 92.1%) in a Hepa1–6 mouse tumor model and increased CD8+ cells in tumor microenvironment. Importantly, NPH16 possessed favorable pharmacokinetic properties with an oral bioavailability of 15.9%. Collectively, compound NPH16 represents a promising PD-1/PD-L1 inhibitor worthy of further investigation as a potential anticancer agent.